Cargando…
Novel paradigm for immunotherapy of ovarian cancer by engaging prophylactic immunity against hepatitis B virus
BACKGROUND: Only eight women out of one hundred diagnosed with ovarian epithelial cancers, which progressed to the clinical stage IV, survive 10 years. First line therapies: surgery, chemotherapy, and radiation therapy inflict very serious iatrogenic consequences. Passive immunotherapy of ovarian ca...
| Autores principales: | , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Springer Berlin Heidelberg
2016
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5130937/ https://www.ncbi.nlm.nih.gov/pubmed/27905089 http://dx.doi.org/10.1186/s40169-016-0125-2 |